{
    "root": "309ff21b-3902-dcc7-e063-6294a90a7eb9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sodium Polystyrene Sulfonate",
    "value": "20250318",
    "ingredients": [
        {
            "name": "SODIUM POLYSTYRENE SULFONATE",
            "code": "1699G8679Z"
        }
    ],
    "indications": "sodium polystyrene sulfonate powder , suspension indicated treatment hyperkalemia . limitation : sodium polystyrene sulfonate powder , suspension used emergency treatment life-threatening hyperkalemia delayed onset action [ pharmacology ( 12.2 ) ] .",
    "contraindications": "oral : average total daily adult dose sodium polystyrene sulfonate powder , suspension 15 g 60 g , administered 15-g dose ( four level teaspoons ) , one four times daily ( 2.1 ) . rectal : average adult dose 30 g 50 g every six hours ( 2.1 ) .",
    "warningsAndPrecautions": "sodium polystyrene sulfonate powder , suspension available follows : ndc 17856-0024-01 sodium polystyrene sulfonate pwd 15 gm cup 50 ct ud ndc 17856-0024-02 sodium polystyrene sulfonate pwd 30 gm cup 50 ct ud store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sodium polystyrene sulfonate powder , suspension contraindicated patients following conditions : •hypersensitivity polystyrene sulfonate resins •obstructive bowel disease •neonates reduced gut motility",
    "indications_original": "Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.\n                  \n                     Limitation of Use:\n                  \n                  Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action\n \n  \n                        [see Clinical Pharmacology (12.2)]\n                     .",
    "contraindications_original": "Oral : The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily ( 2.1 ). Rectal : The average adult dose is 30 g to 50 g every six hours ( 2.1 ).",
    "warningsAndPrecautions_original": "Sodium Polystyrene Sulfonate Powder, for Suspension is available as follows:\n                  ndc 17856-0024-01  SODIUM POLYSTYRENE SULFONATE PWD 15 GM CUP 50 ct UD\n                  ndc 17856-0024-02  SODIUM POLYSTYRENE SULFONATE PWD 30 GM CUP 50 ct UD\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:\n                  •Hypersensitivity to polystyrene sulfonate resins \n    •Obstructive bowel disease \n    •Neonates with reduced gut motility"
}